OrbusNeich said today that it launched the latest version of its dual-therapy stent, the Combo Plus, featuring an antibody biological coating designed to promote vessel healing in patients with complex coronary artery disease.
After the stent is implanted, the biological coating captures endothelial progenitor cells and kicks off formation of an endothelial layer. A coating of bioabsorbable polymer elutes sirolimus to inhibit neointimal hyperplasia, or the growth and movement of vascular smooth muscle cells in the innermost layer of the artery. The accelerated healing process may reduce adverse events and lead to a quicker return of functionality in patients with coronary stenosis, according to the Hong Kong-based company.
The dual therapy stent uses an enhanced balloon catheter, featuring a lower profile design, lubricious coating and reduced shaft diameters.
“Our design improvements provide superior deliverability and powerful performance for complex daily practice,” chairman David Chien said in prepared remarks. “Combo Plus offers physicians a compelling new treatment option for patients with coronary artery disease.”
OrbusNeich 1st launched the Combo dual therapy stent in 2013, touting it as the world’s 1st dual-therapy stent designed to accelerate endothelial coverage while controlling neointimal profileration. The device is supported by a family of clinical studies, totaling more than 6,000 patients across more than 26 countries.
Earlier this year, the company expanded its portfolio to include its Jade and Scoreflex percutaneous transluminal angioplastyballoon devices designed to treat peripheral artery disease. The balloon devices are OrbusNeich’s 1st foray into lower limb and arteriovenous fistula intervention.
